Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

SCYX-1608210 and SCYX-1330682

Human African Trypanosomiasis Research

  • Target disease: HAT
  • PartnersAnacor Pharmaceuticals Inc., USA; Pace University, USA; LMPH, Belgium; SCYNEXIS Inc., USA
  • Leadership: Discovery and Pre-clinical Director: Robert Don; Head of Drug Discovery: Charles Mowbray; Project Coordinator: Stéphanie Braillard
  • Project start: April 2009
  • Funding: Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands;  Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations & individuals.

  • Objective: Select an oxaborole for pre-clinical evaluation

Following extensive pharmacokinetic profiling of many possible back-up compounds to SCYX-7158 for HAT (previously known as the Oxaborole backup programme; see Annual Report 2012), two leads, SCYX-1608210 and SCYX-1330682, were prioritized. Based on available pre-clinical data, it is predicted that these two compounds will likely have shorter half-lives in humans than SCYX-7158. Both compounds have been shown to provide cures in the stage 2 mouse model of HAT. Given the encouraging progress of both fexinidazole (Phase II/III) and SCYX-7158 (Phase I), and as resources are limited, DNDi has chosen to place further development of these two back-up compounds on hold. Work will only recommence should problems be encountered with SCYX- 7158 in clinical development.



Last update: September 2014


Tags: HAT – Sleeping Sickness
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License